21,030 research outputs found
Report on Meteorological Research March 1, 1935 (m-1)
No full textThe object of the report was to elucidate in detail the various features of the research program in meteorology being carried on at the Daniel Guggenheim Airship Institute in Akron, Ohio. Mr. L. J. Fangman, of the U.S. Weather Bureau, was collaborating with the author in carrying out work such as a study of autographic records of the various meteorological elements during frontal passages with a view to the possible prediction of the intensity of the accompanying disturbance as it may affect the operation of aircraft and a study of atmospheric gustiness with a view to finding the dependence between frequency end amplitude of velocity fluctuations and the vertical temperature and velocity gradients
(Fourth) Report on Meteorological Activities at the DGAI (8-1-36)(Weather Bureau Copy)
No full textThis report is on the investigations of frontal phenomena at the Daniel Guggenheim Airship Institute in Akron, Ohio from January 1, 1935 through August 1, 1936. The investigation was carried out with the cooperation of the U.S. Bureau of Aeronautics, the U.S. Weather Bureau, the California Institute of Technology, and the Guggenheim Airship Institute. Mr. R.C. Robinson of the Weather Bureau cooperated with the author in carrying out the investigation. The object of the investigation was to determine the intensity of the atmospheric disturbances (i.e. rapidity of wind shift and gustiness) accompanying the passage of cold fronts, along with a study of the characteristics of the air masses involved and other features which might affect the intensity of the disturbance. The report treated thirty cold fronts which passed the station during 1935 to 1936
Archives and Images as Repositories of Time, Language, and Forms from the Past: A Conversation with Daniel Eisenberg
No full textDaniel Akech
No full textabstract: Daniel was a little boy when the war came to his village. He witnessed people being shot and running for shelter. There was no food or water so he drank urine and ate tree leaves.
“Lost Boys Found” is an ongoing, interdisciplinary project that is collecting, recording and archiving the oral histories of the Lost Boys/Girls of Sudan. The collection is a work-in-progress, seeking to record the oral history of as many Lost Boys/Girls as are willing, and will be used in a future book.Age: 24Region: Upper NileThis picture and bio was donated to the "Lost Boys Found" oral history project from The Arizona Lost Boys Cente
Daniel Emmett postcard
No full textPostcard of Daniel Emmett and his home in Mount Vernon, Ohio. Emmett is considered to be the author of the antebellum song "Dixie," written in 1859, which became the unofficial song of the Confederate soldiers during the American Civil War. He was born in Mount Vernon in 1815 and taught himself the fiddle, and later became associated with minstrel shows and helped to define that genre. Minstrel shows traveled around the United States, presenting skits and musical performances. Emmett also composed many other songs, including "Old Dan Tucker," "Turkey in the Straw," and "The Blue Tail Fly." He died in 1904
Daniel Jau Maper
No full textabstract: Daniel Jau Maper was herding cattle when Arabs attacked his village.
“Lost Boys Found” is an ongoing, interdisciplinary project that is collecting, recording and archiving the oral histories of the Lost Boys/Girls of Sudan. The collection is a work-in-progress, seeking to record the oral history of as many Lost Boys/Girls as are willing, and will be used in a future book.Age: 27Region: Upper NileThis picture and bio was donated to the "Lost Boys Found" oral history project from The Arizona Lost Boys Cente
Daniel A. Ngor
No full textWhen Daniel was five years old Arab soldiers attacked his village.
“Lost Boys Found” is an ongoing, interdisciplinary project that is collecting, recording and archiving the oral histories of the Lost Boys/Girls of Sudan. The collection is a work-in-progress, seeking to record the oral history of as many Lost Boys/Girls as are willing, and will be used in a future book.Age : 23Region: Upper NileThis picture and bio was donated to the "Lost Boys Found" oral history project from The Arizona Lost Boys Cente
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
No full textWołowiec Łukasz, Rogowicz Daniel, Kałużny Krystian, Kałużna Anna, Zukow Walery. Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? Journal of Education, Health and Sport. 2017;7(8):836-846. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.893351
http://ojs.ukw.edu.pl/index.php/johs/article/view/4833
https://pbn.nauka.gov.pl/sedno-webapp/works/831626
The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017).
1223 Journal of Education, Health and Sport eISSN 2391-8306 7
© The Authors 2017;
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.
This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial
use, distribution and reproduction in any medium, provided the work is properly cited.
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 01.07.2017. Revised: 10.07.2017. Accepted: 31.07.2017.
Doustny antykoagulant niebędący antagonistą witaminy K w profilaktyce i leczeniu żylnej choroby zakrzepowo-zatorowej. Co wyróżnia betriksaban?
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
Łukasz Wołowiec1, Daniel Rogowicz1, Krystian Kałużny2, Anna Kałużna2, Walery Zukow3
1II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu
2Katedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu
3Katedra Gospodarki Przestrzennej i Turyzmu, Wydział Nauk o Ziemi, Uniwersytet Mikołaja Kopernika
w Toruniu
Streszczenie
W skład pojęcia żylnej choroby zakrzepowo - zatorowej (z ang. venous thromboembolism, VTE) wchodzi zakrzepica żył głębokich oraz zatorowość płucna. VTE jest jedną z wiodących przyczyn zachorowalności i śmiertelności na całym świecie, trzecim najczęstszym schorzeniem układu sercowo-naczyniowego po ostrym zespole wieńcowym i udarze mózgu.
Do niedawana podstawą profilaktyki i leczenia VTE były: heparyna niefrakcjonowana, heparyna drobnocząsteczkowa i warfaryna. Aktualnie substancje te są stopniowo zastępowane przez doustne antykoagulanty niebędące antagonistami witaminy K (z. ang. non-vitamin K antagonist oral anticoagulants , NOACs).
Betrixaban jest bezpośrednim inhibitorem czynnika Xa, wyróżnia się spośród pozostałych NOACs nieznacznym udziałem nerek i wątroby w jego metabolizmie, oraz długim okresem półtrwania. Dnia 23 czerwca FDA i koncern Portola Pharmaceuticals ogłosiły zatwierdzenie betrixabanu w celu zmniejszenia ryzyka VTE u dorosłych hospitalizowanych z powodu ostrej choroby, z ograniczoną mobilnością lub innymi czynnikami ryzyka VTE. W swoim komunikacie FDA oświadczyła, że lek został zatwierdzony na podstawie danych z badania APEX (Acute Medically III VTE Prevention With Extended Duration Betrixaban trial).
W badaniu tym porównywano częstość występowania VTE i zgonów w ostrych chorych leczonych betriksabanem przez 35-42 dni lub enoksaparyną przez 6-14 dni. Wszyscy uczestnicy badania byli hospitalizowani z powodu: objawów niewydolności serca, niewydolności oddechowej, zakażenia (za wyjątkiem wstrząsu septycznego), zaburzeń reumatycznych lub udaru niedokrwiennego. Stosowanie betrixabanu związanego było z około 30% redukcją śmiertelnych lub nieodwracalnych zdarzeń niedokrwiennych oraz krwawień w porównaniu z enoksaparyną stosowaną w dawce standardowej, a następnie kontynuowanej placebo.
Słowa kluczowe: doustne antykoagulanty niebędące antagonistami witaminy K, nowe doustne antykoagulanty, betriksaban, żylna choroba zakrzepowo-zatorowa
Abstract
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide. VTE is the third most common cardiovascular illness after acute coronary syndrome and stroke.
Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the foundation of venous thromboembolism (VTE) prevention and treatment but are being replaced step-by-step by recently approved non-vitamin K antagonist oral anticoagulants (NOACs).
Betrixaban is a direct FXa inhibitor with clear pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life. FDA and Portola Pharmaceuticals on June 23 announced the approval of betrixaban to reduce the risk of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have restricted mobility or other risk factors for thromboembolic complications. FDA stated that it approved the drug on the basis of data from the Acute Medically Ill VTE Prevention With
Extended Duration Betrixaban (APEX) trial.
The APEX trial compared thromboembolic event and death rates in acutely ill patients treated with betrixaban capsules for 35–42 days or subcutaneously administered enoxaparin for 6–14 days. All study participants had been hospitalized for heart failure, respiratory failure, infection without septic shock, rheumatic disorders, or ischemic stroke. Among hospitalized medically ill patients, extended-duration betrixaban demonstrates a favorable net clinical outcome and is associated with an ≈ 30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin followed by placebo.
Key words: non-vitamin K oral anticoagulants, new oral anticoagulants, betrixaban, venous thromboembolismWołowiec Łukasz, Rogowicz Daniel, Kałużny Krystian, Kałużna Anna, Zukow Walery. Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? Journal of Education, Health and Sport. 2017;7(8):836-846. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.893351
http://ojs.ukw.edu.pl/index.php/johs/article/view/4833
https://pbn.nauka.gov.pl/sedno-webapp/works/83162
Personal Papers (MS 80-0002)
No full textLetter from Mary T. Steyn of The Readers Digest to Daniel W. Kempner providing some information on the author of an article he was asking about
Meet Daniel Melnick author of The Ash Tree
No full textMeet Daniel Melnick author of The Ash Tree. It tells a timeless story of the romance and marriage between an American Armenian girl and an immigrant who survived the 1915 Armenian Genocide in Turkey. In the aftermath of the Genocide from the 20s through the early 70s, the couple and their three children become vivid, quintessentially American characters, only for tragedy to find them again, echoing the staggering losses of 1915. The cover painting with its frayed, whitewashed frame is by the author’s wife, Jeanette Arax Melnick, and the novel is based partly on the lives of her family. Combining history and fictionalized memoir, The Ash Tree is an important, beautifully written novel of survival, new life, and heartbreak. Available from independent bookstores, Barnes and Noble, and Amazon.com. Further information at www.danielmelnick.com. Price: $25. ISBN: 9780981854762
- …
